Drug- and toxin-induced hepatotoxicity;Medikamenten- und fremdstoffbedingte hepatotoxizität

Zeitschrift fur Gastroenterologie

Volumn 41, Issue 6, 2003, Pages 565-578

  Grunhage F ^a   Fischer, H P ^a   Sauerbruch, T ^a   Reichel, Christoph ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Hepatitis; Hepatotoxicity; Liver; Toxins

Indexed keywords

ACETYLCYSTEINE; AMOXICILLIN PLUS CLAVULANIC ACID; BILIRUBIN; CARBAMAZEPINE; CHLORPROMAZINE; CREATININE; DAPSONE; DEFEROXAMINE; DIHYDRALAZINE; ERYTHROMYCIN; HALOTHANE; ISONIAZID; METHOXYFLURANE; METHYLDOPA; MINOCYCLINE; NITROFURANTOIN; OXYPHENISATINE; PENICILLIN G; PHENYLBUTAZONE; PHENYTOIN; PREDNISONE; PROCAINAMIDE; PROTHROMBIN; SILIBININ; SULFONAMIDE; SULINDAC; TETRACYCLINE; TIENILIC ACID; UNINDEXED DRUG; VITAMIN K GROUP;

CHOLESTASIS; CHRONIC HEPATITIS; CLINICAL FEATURE; DRUG INDUCED DISEASE; FATTY ACID OXIDATION; GENE MUTATION; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HUMAN; LIPID PEROXIDATION; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER TOXICITY; MITOCHONDRIAL RESPIRATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN SYNTHESIS INHIBITION; REVIEW; STEATOSIS;

ANTIDOTES; BIOPSY; CHOLESTASIS; CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; DRUG HYPERSENSITIVITY; FATTY LIVER; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS, TOXIC; HUMANS; LIPID PEROXIDATION; LIVER; LIVER CIRRHOSIS; LIVER DISEASES; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MUTATION; OXIDATIVE STRESS; PHARMACEUTICAL PREPARATIONS; PLANTS, MEDICINAL; PROGNOSIS; RISK FACTORS; TOXINS, BIOLOGICAL;

EID: 0038110878     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-39650     Document Type: Review

References (172)

1. Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med 1992; 232 (2): 133-138
2. Sameshima Y, Shiozaki Y, Mizuno T et al. Clinical statistics on drug-induced liver injuries. Drug-induced liver injuries in Japan in the past 30 years. Nippon Shokakibyo Gakkai Zasshi 1974; 71 (8): 799-807
3. Garcia Rodriguez LA, Perez Gutthann S, Walker AM et al. The role of non-steroidal anti-inflammatory drugs in acute liver injury. Br Med J 1992; 305 (6858): 865-868
4. Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut 1999; 44 (5): 731-735
5. Neeleman J, Wessely S. Drugs taken in fatal and non-fatal self-poisoning: a study in south London. Acta Psychiatr Scand 1997; 95 (4): 283-287
6. O'Grady JG, Wendon J, Tan KC et al. Liver transplantation after paracetamol overdose. Br Med J 1991; 303 (6796): 221-223
7. Turvill JL, Burroughs AK, Moore KP. Change in occurrence of paracetamol overdose in UK after introduction of blister packs. Lancet 2000; 355 (9220): 2048-2049
8. Cooksley WG, Cowen AE, Powell LW. The incidence of oxyphenisatin ingestion in active chronic hepatitis: a prospective controlled study of 29 patients. Aust N Z J Med 1973; 3 (2): 124-128
9. Goldstein GB, Lam KC, Mistilis SP. Drug-induced active chronic hepatitis. Am J Dig Dis 1973; 18 (3): 177-184
10. Dietrichson O, Juhl E, Nielsen JO et al. The incidence of oxyphenisatin-induced liver damage in chronic non-alcoholic liver disease. A controlled investigation. Scand J Gastroenterol 1974; 9 (5): 473-478
11. Lindberg J, Lindholm A, Lundin P et al. Trigger factors and HL-A antigens in chronic active hepatitis. Br Med J 1975; 4 (5988): 77-79
12. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13 (3): 372-374
13. Desmeules J, Bonabry P, Dayer P. Hepatic metabolism of drugs. In: Bircher J, Benhamou J, McIntyre N et al (Hrsg). Oxford Textbook of Clinical Hepatology. New York: Oxford University Press 1999; 145-164
14. Sipes IG, Slocumb ML, Perry DF et al. 2,4,5,2′,4′,5′-Hexachlorobiphenyl: distribution, metabolism, and excretion in the dog and the monkey. Toxicol Appl Pharmacol 1982; 65 (2): 264-272
15. Dianzani MU. The role of free radicals in liver damage. Proc Nutr Soc 1987; 46 (1): 43-52
16. Williams AT, Burk RF. Carbon tetrachloride hepatotoxicity: an example of free radical-mediated injury. Semin Liver Dis 1990; 10 (4): 279-284
17. Lindros KO, Cai YA, Penttila KE. Role of ethanol-inducible cytochrome P-450 IIE1 in carbon tetrachloride-induced damage to centrilobular hepatocytes from ethanol-treated rats. Hepatology 1990; 12 (5): 1092-1097
18. Persson JO, Terelius Y, Ingelman-Sundberg M. Cytochrome P-450-dependent formation of reactive oxygen radicals: isozyme-specific inhibition of P-450-mediated reduction of oxygen and carbon tetrachloride. Xenobiotica 1990; 20 (9): 887-900
19. Recknagel RO, Glende EA. Carbon tetrachloride hepatotoxicity: an example of lethal cleavage. CRC Critical Reviews in Toxicology 2 1973; 263-297
20. Judah JD, McLean AE, McLean EK. Biochemical mechanisms of liver injury. Am J Med 1970; 49: 609-16
21. Faber J, Finkelstein JD. Inherited metabolic defects involving the liver. Med Clin North Am 1975; 59 (4): 919-925
22. Boll M, Weber LW, Becker E et al. Mechanism of carbon tetrachloride-induced hepatotoxicity. Hepatocellular damage by reactive carbon tetrachloride metabolites. Z Naturforsch [C] 2001; 56 (7-8): 649-59
23. Minoda Y, Kharasch ED. Halothane-dependent lipid peroxidation in human liver microsomes is catalyzed by cytochrome P4502A6 (CYP2A6). Anesthesiology 2001; 95 (2): 509-514
24. Bessems JG, Vermeulen NP. Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. Crit Rev Toxicol 2001; 31 (1): 55-138
25. Mitchell JR, Jollow DJ, Potter WZ et al. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther 1973; 187 (1): 185-194
26. Mitchell JR, Jollow DJ, Potter WZ et al. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther 1973; 187 (1): 211-217
27. Corcoran GB, Mitchell JR, Vaishnav YN et al. Evidence that acetaminophen and N-hydroxyacetaminophen form a common arylating intermediate, N-acetyl-p-benzoquinoneimine. Mol Pharmacol 1980; 18 (3): 536-542
28. Dahlin DC, Miwa GT, Lu AY et al. N-acetyl-p-benzoquinoneimine: a cytochrome P-450-mediated oxidation product of acetaminophen. Proc Natl Acad Sci U S A 1984; 81 (5): 1327-1331
29. Jollow DJ, Mitchell JR, Potter WZ et al. Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J Pharmacol Exp Ther 1973; 187 (1): 195-202
30. Potter WZ, Davis DC, Mitchell JR et al. Acetaminophen-induced hepatic necrosis. 3. Cytochrome P-450-mediated covalent binding in vitro. J Pharmacol Exp Ther 1973; 187 (1): 203-210
31. Streeter AJ, Dahlin DC, Nelson SD et al. The covalent binding of acetaminophen to protein. Evidence for cysteine residues as major sites of arylation in vitro. Chem Biol Interact 1984; 48 (3): 349-366
32. Hoffmann KJ, Streeter AJ, Axworthy DB et al. Identification of the major covalent adduct formed in vitro and in vivo between acetaminophen and mouse liver proteins. Mol Pharmacol 1985; 27 (5): 566-573
33. Hongslo JK, Smith CV, Brunborg G et al. Genotoxicity of paracetamol in mice and rats. Mutagenesis 1994; 9 (2): 93-100
34. Yamada T. Covalent binding theory for acetaminophen hepatotoxicity. Gastroenterology 1983; 85 (1): 202-203
35. Nelson SD. Mechanisms of the formation and disposition of reactive metabolites that can cause acute liver injury. Drug Metab Rev 1995; 27 (1-2): 147-177
36. Beitia G, Cobreros A, Sainz L et al. 3,4-Methylenedioxymethamphetamine (ecstasy)-induced hepatotoxicity: effect on cytosolic calcium signals in isolated hepatocytes. Liver 1999; 19 (3): 234-241
37. Berson A, Schmets L, Fisch C et al. Inhibition by nilutamide of the mitochondrial respiratory chain and ATP formation. Possible contribution to the adverse effects of this antiandrogen. J Pharmacol Exp Ther 1994; 270 (1): 167-176
38. Yasuda SU, Sausville EA, Hutchins JB et al. Amiodarone-induced lymphocyte toxicity and mitochondrial function. J Cardiovasc Pharmacol 1996; 28 (1): 94-100
39. Pessayre D, Mansouri A, Haouzi D et al. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol 1999; 15 (6): 367-373
40. Josephson SA, Kessel ER. Amiodarone hepatotoxicity. Dig Dis 1997; 15 (4-5): 312
41. Fromenty B, Fisch C, Labbe G et al. Amiodarone inhibits the mitochondrial beta-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther 1990; 255 (3): 1371-1376
42. Fromenty B, Fisch C, Berson A et al. Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II. J Pharmacol Exp Ther 1990; 255 (3): 1377-1384
43. Weiland T. Poisonous principles of mushrooms of the genus Amanita. Science 1968; 159: 946-952
44. Faulstich H. New aspects of amanita poisoning. Klin Wochenschr 1979; 57 (21): 1143-1152
45. Himmelmann A, Mang G, Schnorf-Huber S. Lethal ingestion of stored Amanita phalloides mushrooms. Swiss Med Wkly 2001; 131 (41-42): 616-617
46. Cochet-Meilhac M, Chambon P. Animal DNA-dependent RNA polymerases. II. Mechanism of the inhibition of RNA polymerases B by amatoxins. Biochim Biophys Acta 1974; 353 (2): 160-184
47. Zimmerman HJ. Chemical hepatic injury and its detection. In: Plaa G, Hewitt WR (Hrsg). Toxicology of the liver. New York: Raven Press 1982; 1-45
48. Kopelman H, Robertson MH, Sanders PG et al. The Epping jaundice. Br Med J 1966; 5486: 514-516
49. Kopelman H. The Epping jaundice after two years. Postgrad Med J 1968; 44 (507): 78-81
50. Williams SV, Bryan JA, Burk JR et al. Letter: Toxic hepatitis and methylenedianiline. N Engl J Med 1974; 291 (23)
51. Zimmerman HJ, Lewis JH. Drug-induced cholestasis. Med Toxicol 1987; 2: 112-160
52. Huang L, Smit JW, Meijer DK et al. Mrp2 is essential for estradiol-17beta (beta-D-glucuronide)-induced cholestasis in rats. Hepatology 2000; 32 (1): 66-72
53. Stieger B, Fattinger K, Madon J et al. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 2000; 118 (2): 422-430
54. Schmid M. Cutaneous porphyria in Turkey. N Engl J Med 1960; 272: 546-550
55. Peters HA. Hexachlorobenzene poisoning in Turkey. Fed Proc 1976; 35 (12): 2400-2403
56. de Matteis F, Gibbs AH, Jackson AH et al. Conversion of liver haem into N-substituted porphyrins or green pigments. Nature of the substituent at the pyrrole nitrogen atom. FEBS Lett 1980; 119 (1): 109-112
57. Doss MO. Porphyria cutanea tarda (chronic hepatic porphyria): new aspects on pathogenesis, diagnosis and therapy with a review of the workshop, "Cutaneous porphyrias" at the 17th World Congress of Dermatology in Berlin 1987. Z Hautkr 1988; 63 (4): 282-289
58. De Catabbi SCB, Aldonatti C, de Viale LC. Heme metabolism after discontinued hexachlorobenzene administration in rats: possible irreversible changes and biomarker for hexachlorobenzene persistence. Comp Biochem Physiol C Toxicol Pharmacol 2000; 127 (2): 165-175
59. Essigmann JM, Croy RG, Bennett RA et al. Metabolic activation of aflatoxin B1: patterns of DNA adduct formation, removal, and excretion in relation to carcinogenesis. Drug Metab Rev 1982; 13 (4): 581-602
60. Alpert ME, Davidson CS. Mycotoxins. A possible cause of primary carcinoma of the liver. Am J Med 1969; 46 (3): 325-329
61. Peers FG, Linsell CA. Dietary aflatoxins and liver cancer - a population based study in Kenya. Br J Cancer 1973; 27 (6): 473-484
62. Enwonwu CO. The role of dietary aflatoxin in the genesis of hepatocellular cancer in developing countries. Lancet 1984; 2 (8409): 956-958
63. Swenberg JA, Bogdanffy MS, Ham A et al. Formation and repair of DNA adducts in vinyl chloride- and vinyl fluoride-induced carcinogenesis. IARC Sci Publ 1999; (150): 29-43
64. Kielhorn J, Melber C, Wahnschaffe U et al. Vinyl chloride: still a cause for concern. Environ Health Perspect 2000; 108 (7): 579-588
65. Pereg D, Robertson LW, Gupta RC. DNA adduction by polychlorinated biphenyls: adducts derived from hepatic microsomal activation and from synthetic metabolites. Chem Biol Interact 2002; 139 (2): 129-144
66. O'Brien T, Babcock G, Cornelius J et al. A comparison of apoptosis and necrosis induced by hepatotoxins in HepG2 cells. Toxicol Appl Pharmacol 2000; 164 (3): 280-290
67. Aguilar F, Hussain SP, Cerutti P. Aflatoxin B1 induces the transversion of G->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci U S A 1993; 90 (18): 8586-8590
68. Guengerich FP, Watanabe PG. Metabolism of [14C]- and [36C]-labeled vinyl chloride in vivo and in vitro. Biochem Pharmacol 1979; 28 (5): 589-596
69. Tamburro CH, Makk L, Popper H. Early hepatic histologic alterations among chemical (vinyl monomer) workers. Hepatology 1984; 4 (3): 413-418
70. Mundt KA, Dell LD, Austin RP et al. Historical cohort study of 10 109 men in the North American vinyl chloride industry, 1942-72: update of cancer mortality to 31 December 1995. Occup Environ Med 2000; 57 (11): 774-781
71. Binetti R, Costamagna FM, Marcello I. Vinyl chloride and 1,2-dichloroethane: classification and assessment of carcinogenicity, guidelines, threshold values, and standards developed by national and international entities, organizations, and agencies. Epidemiol Prev 2001; 25 (1): 31-39
72. Smela ME, Currier SS, Bailey EA et al. The chemistry and biology of aflatoxin B (1): from mutational spectrometry to carcinogenesis. Carcinogenesis 2001; 22 (4): 535-545
73. Ward E, Boffetta P, Andersen A et al. Update of the follow-up of mortality and cancer incidence among European workers employed in the vinyl chloride industry. Epidemiology 2001; 12 (6): 710-718
74. Hollstein M, Marion MJ, Lehman T et al. p53 mutations at A: T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. Carcinogenesis 1994; 15 (1): 1-3
75. Kenna JG, Satoh H, Christ DD et al. Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J Pharmacol Exp Ther 1988; 245 (3): 1103-1109
76. Gut J, Christen U, Huwyler J. Mechanisms of halothane toxicity: novel insights. Pharmacol Ther 1993; 58 (2): 133-155
77. Volpes R, van den Oord JJ, Desmet VJ. Can hepatocytes serve as 'activated' immunomodulating cells in the immune response? J Hepatol 1992; 16 (1-2): 228-240
78. Pessayre D. Role of reactive metabolites in drug-induced hepatitis. J Hepatol 1995; 23 (Suppl 1): 16-24
79. Vergani D, Mieli-Vergani G, Alberti A et al. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med 1980; 303 (2): 66-71
80. Satoh H, Fukuda Y, Anderson DK et al. Immunological studies on the mechanism of halothane-induced hepatotoxicity: immunohistochemical evidence of trifluoroacetylated hepatocytes. J Pharmacol Exp Ther 1985; 233 (3): 857-862
81. Loeper J, Descatoire V, Amouyal G et al. Presence of covalently bound metabolites on rat hepatocyte plasma membrane proteins after administration of isaxonine, a drug leading to immunoallergic hepatitis in man. Hepatology 1989; 9 (5): 675-678
82. Beaune PH, Lecoeur S. Immunotoxicology of the liver: adverse reactions to drugs. J Hepatol 1997; 26 (Suppl 2): 37-42
83. Dansette PM, Bonierbale E, Minoletti C et al. Drug-induced immunotoxicity. Eur J Drug Metab Pharmacokinet 1998; 23 (4): 443-451
84. Satoh H, Gillette JR, Davies HW et al. Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats. Mol Pharmacol 1985; 28 (5): 468-474
85. Satoh H, Gillette JR, Takemura T et al. Investigation of the immunological basis of halothane-induced hepatotoxicity. Adv Exp Med Biol 1986; 197: 657-673
86. Satoh H, Martin BM, Schulick AH et al. Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase. Proc Natl Acad Sci U S A 1989; 86 (1): 322-326
87. Musch E, Eichelbaum M, Wang JK et al. Incidence of hepatotoxic side effects during antituberculous therapy (INH, RMP, EMB) in relation to the acetylator phenotype (author's transl). Klin Wochenschr 1982; 60 (10): 513-519
88. Ohno M, Yamaguchi I, Yamamoto I et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 2000; 4 (3): 256-261
89. Huang YS, Chern HD, Su WJ et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35 (4): 883-889
90. Szumlanski CL, Honchel R, Scott MC et al. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 1992; 2 (4): 148-159
91. Dubinsky MC, Lamothe S, Yang HY et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118 (4): 705-713
92. Szumlanski C, Otterness D, Her C et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996; 15 (1): 17-30
93. Evans WE, Hon YY, Bomgaars L et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19 (8): 2293-2301
94. Bertilsson L, Dahl ML, Dalen P et al. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002; 53 (2): 111-122
95. Ishak KG. Drug-Induced Liver Injury Pathology. In: Bloomer JR, Goodman ZD, Ishak KG (Hrsg). Clinical and Pathological correlations in liver disease: Approaching the next millenium. Washington DC: The Armed Forces Institute of Pathology 1998; 236-251
96. Larrey D, Erlinger S. Drug-induced cholestasis. Baillieres Clin Gastroenterol 1988; 2 (2): 423-452
97. Levy M, Goodman MW, Van Dyne BJ et al. Granulomatous hepatitis secondary to carbamazepine. Ann Intern Med 1981; 95 (1): 64-65
98. Larrey D, Hadengue A, Pessayre D et al. Carbamazepine-induced acute cholangitis. Dig Dis Sci 1987; 32 (5): 554-557
99. Ishak KG, Zimmerman HJ. Hepatotoxic effects of the anabolic/androgenic steroids. Semin Liver Dis 1987; 7 (3): 230-236
100. Zimmerman HJ. Drug-induced liver injury clinical. In: Bloomer JR, Goodman ZD, Ishak KG (Hrsg). Clinical and pathological correlations in liver disease: Approaching the next millenium. Washington DC: The Armed Forces Institute of Pathology 1998; 252-269
101. Farrell GC. Drug-induced liver injury. New York: Chruchill Livingstone 1994
102. Zimmerman HJ. Hepatotoxicity. In: The adverse effects of drugs and other chemicals on the liver. New York: Appleton Century Crofts 1978
103. Zimmerman HJ, Ishak KG. Non-alcoholic steatohepatitis and other forms of pseudoalcoholic liver disease. In: Hall P (Hrsg). Alcoholic liver disease. Pathology and Pathogenesis. London: Arnold 1995; 175-198
104. de Knegt RJ. Non-alcoholic steatohepatitis: clinical significance and pathogenesis. Scand J Gastroenterol Suppl 2001; 234: 88-92
105. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001; 121 (3): 710-723
106. Poucell S, Ireton J, Valencia-Mayoral P et al. Amiodarone-associated phospholipidosis and fibrosis of the liver. Light, immunohistochemical, and electron microscopic studies. Gastroenterology 1984; 86 (5 Pt 1): 926-936
107. Lewis JH, Ranard RC, Caruso A et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology 1989; 9 (5): 679-685
108. Lewis JH, Mullick F, Ishak KG et al. Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum Pathol 1990; 21 (1): 59-67
109. Langman G, Hall PM, Todd G. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol 2001; 16 (12): 1395-1401
110. Seki K, Minami Y, Nishikawa M et al. "Nonalcoholic steatohepatitis" induced by massive doses of synthetic estrogen. Gastroenterol Jpn 1983; 18 (3): 197-203
111. Nemoto Y, Saibara T, Ogawa Y et al. Tamoxifen-induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen. Intern Med 2002; 41 (5): 345-350
112. Rahmat J, Gelfand RL, Gelfand MC et al. Captopril-associated cholestatic jaundice. Ann Intern Med 1985; 102 (1): 56-58
113. Crantock L, Prentice R, Powell L. Cholestatic jaundice associated with captopril therapy. J Gastroenterol Hepatol 1991; 6 (5): 528-530
114. Nissan A, Spira RM, Seror D et al. Captopril-associated "pseudocholangitis". A case report and review of the literature. Arch Surg 1996; 131 (6): 670-671
115. Hurlimann R, Binek J, Oehlschlegel C et al. Enalapril (Reniten)-associated toxic hepatitis. Schweiz Med Wochenschr 1994; 124 (29): 1276-1280
116. Dowsett JF, Gillow T, Heagerty A et al. Amoxycillin/clavulanic acid (Augmentin)-induced intrahepatic cholestasis. Dig Dis Sci 1989; 34 (8): 1290-1293
117. Koek GH, Stricker BH, Blok AP et al. Flucloxacillin-associated hepatic injury. Liver 1994; 14 (5): 225-229
118. Pedro-Botet J, Supervia A, Barranco C et al. Intrahepatic cholestasis without hepatitis induced by amoxycillin/clavulanic acid. J Clin Gastroenterol 1996; 23 (2): 137-138
119. Desmet VJ, van Eyken P, Roskams T. Histopathology of vanishing bile duct diseases. Adv Clin Path 1998; 2 (2): 87-99
120. Geubel AP, Sempoux CL. Drug and toxin-induced bile duct disorders. J Gastroenterol Hepatol 2000; 15 (11): 1232-1238
121. Bolton JS, Bowen JC. Biliary sclerosis associated with hepatic artery infusion of floxuridine. Surgery 1986; 99 (1): 119-122
122. Aldrighetti L, Arru M, Ronzoni M et al. Extrahepatic biliary stenoses after hepatic arterial infusion (HAI) of floxuridine (FUdR) for liver metastases from colorectal cancer. Hepatogastroenterology 2001; 48 (41): 1302-1307
123. Dikengil A, Siskind BN, Morse SS et al. Sclerosing cholangitis from intraarterial floxuridine. J Clin Gastroenterol 1986; 8 (6): 690-693
124. Hohn D, Melnick J, Stagg R et al. Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. J Clin Oncol 1985; 3 (1): 98-102
125. Kemeny MM, Battifora H, Blayney DW et al. Sclerosing cholangitis after continuous hepatic artery infusion of FUDR. Ann Surg 1985; 202 (2): 176-181
126. Shea WJ Jr, Demas BE, Goldberg HI et al. Sclerosing cholangitis associated with hepatic arterial FUDR chemotherapy: radiographic-histologic correlation. AJR Am J Roentgenol 1986; 146 (4): 717-721
127. Mallat A, Zafrani ES, Metreau JM et al. Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts. Dig Dis Sci 1997; 42 (7): 1486-1488
128. Valla D, Le MG, Poynard T et al. Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study. Gastroenterology 1986; 90 (4): 807-811
129. Bras G, Brandt KH. Vascular disorders. In: MacSween RNM, Anthony PP, Scheur PJ (Hrsg). Pathology of the liver. Edinburgh: Chruchill Livingstone 1987; 478-502
130. Zafrani ES, Pinaudeau Y, Dhumeau D. Drug-induced vascular lesions of the liver. Arch Intern Med 1983; 143: 395
131. Modzelewski JR Jr, Daeschner C, Joshi VV et al. Veno-occlusive disease of the liver induced by low-dose cyclophosphamide. Mod Pathol 1994; 7 (9): 967-972
132. Hazar V, Kutluk T, Akyuz C et al. Veno-occlusive disease-like hepatotoxicity in two children receiving chemotherapy for Wilms' tumor and clear cell sarcoma of kidney. Pediatr Hematol Oncol 1998; 15 (1): 85-89
133. Chitturi S, Farrell GC. Herbal hepatotoxicity: an expanding but poorly defined problem. J Gastroenterol Hepatol 2000; 15 (10): 1093-1099
134. Valla D, Benhamou JP. Drug-induced vascular and sinusoidal lesions of the liver. Baillieres Clin Gastroenterol 1988; 2 (2): 481-500
135. Zafrani ES, von Pinaudeau Y, Dhumeaux D. Drug-induced vascular lesions of the liver. Arch Intern Med 1983; 143 (3): 495-502
136. Edmondson HA, Henderson B, Benton B. Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med 1976; 294 (9): 470-472
137. Klatskin G. Hepatic tumors: possible relationship to use of oral contraceptives. Gastroenterology 1977; 73 (2): 386-394
138. Metzler M, Degen GH. Sex hormones and neoplasia: liver tumors in rodents. Arch Toxicol Suppl 1987; 10: 251-263
139. Scott LD, Katz AR, Duke JH et al. Oral contraceptives, pregnancy, and focal nodular hyperplasia of the liver. JAMA 1984; 251 (11): 1461-1463
140. Falk H, Herbert J, Crowley S et al. Epidemiology of hepatic angiosarcoma in the United States: 1964-1974. Environ Health Perspect 1981; 41: 107-113
141. Zafrani ES. Update on vascular tumours of the liver. J Hepatol 1989; 8 (1): 125-130
142. van Kaick G, Wesch H. The German Thorotrast study. In: van Kaick G, Muth H, Kaul A (Hrsg). Luxembourg: European Communities 1984; 190-211
143. Picciotto A, Campo N, Brizzolara R et al. Chronic hepatitis induced by Jin Bu Huan. J Hepatol 1998; 28 (1): 165-167
144. Woolf GM, Petrovic LM, Rojter SE et al. Acute hepatitis associated with the Chinese herbal product jin bu huan. Ann Intern Med 1994; 121 (10): 729-735
145. Strahl S, Ehret V, Dahm HH et al. Necrotizing hepatitis after taking herbal remedies. Dtsch Med Wochenschr 1998; 123 (47): 1410-1414
146. Benninger J, Schneider HT, Schuppan D et al. Acute hepatitis induced by greater celandine (Chelidonium majus). Gastroenterology 1999; 117 (5): 1234-1237
147. Larrey D, Vial T, Pauwels A et al. Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann Intern Med 1992; 117 (2): 129-132
148. Mostefa-Kara N, Pauwels A, Pines E et al. Fatal hepatitis after herbal tea. Lancet 1992; 340 (8820): 674
149. Kraft M, Spahn TW, Menzel J et al. Fulminant liver failure after administration of the herbal antidepressant Kava-Kava. Dtsch Med Wochenschr 2001; 126 (36): 970-972
150. Lucena MI, Camargo R, Andrade RJ et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001; 33 (1): 123-130
151. Aithal GP, Rawlins MD, Day CP. Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J Hepatol 2000; 33 (6): 949-952
152. Maria VA, Pinto L, Victorino RM. Lymphocyte reactivity to ex-vivo drug antigens in drug-induced hepatitis. J Hepatol 1994; 21 (2): 151-158
153. Maria VA, Victorino RM. Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury. PG - 534-40. Gut 1997; 41 (4): 534-540
154. Smilkstein MJ, Knapp GL, Kulig KW et al. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med 1988; 319 (24): 1557-1562
155. Brotodihardjo AE, Batey RG, Farrell GC et al. Hepatotoxicity from paracetamol self-poisoning in western Sydney: a continuing challenge. Med J Aust 1992; 157 (6): 382-385
156. McClain CJ, Price S, Barve S et al. Acetaminophen hepatotoxicity: An update. Curr Gastroenterol Rep 1999; 1 (1): 42-49
157. Jacobs J, Greene H, Gendel BR. Acute iron intoxication. N Engl J Med 1965; 273 (21): 1124-1127
158. Blanc P, Hryhorczuk D, Danel I. Deferoxamine treatment of acute iron intoxication in pregnancy. Obstet Gynecol 1984; 64 (3 Suppl): 12S-14S
159. Mahoney JR Jr, Hallaway PE, Hedlund BE et al. Acute iron poisoning. Rescue with macromolecular chelators. J Clin Invest 1989; 84 (4): 1362-1366
160. Flora K, Hahn M, Rosen H et al. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 1998; 93 (2): 139-143
161. Floersheim GL, Weber O, Tschumi P et al. Clinical death-cap (Amanita phalloides) poisoning: prognostic factors and therapeutic measures. Analysis of 205 cases. Schweiz Med Wochenschr 1982; 112 (34): 1164-1177
162. Mills RM Jr. Severe hypersensitivity reactions associated with allopurinol. JAMA 1971; 216 (5): 799-802
163. Lang PG Jr. Severe hypersensitivity reactions to allopurinol. South Med J 1979; 72 (11): 1361-1368
164. Al-Kawas FH, Seeff LB, Berendson RA et al. Allopurinol hepatotoxicity. Report of two cases and review of the literature. Ann Intern Med 1981; 95 (5): 588-590
165. Iveson TJ, Ryley NG, Kelly PM et al. Diclofenac associated hepatitis. J Hepatol 1990; 10 (1): 85-89
166. Sallie RW, McKenzie T, Reed WD et al. Diclofenac hepatitis. Aust N Z J Med 1991; 21 (2): 251-255
167. O'Grady JG, Alexander GJ, Hayllar KM et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97 (2): 439-445
168. Katsinelos P, Vasiliadis T, Xiarchos P et al. Ursodeoxycholic acid (UDCA) for the treatment of amoxycillin-clavulanate potassium (Augmentin)-induced intra-hepatic cholestasis: report of two cases. Eur J Gastroenterol Hepatol 2000; 12 (3): 365-368
169. Cicognani C, Malavolti M, Morselli-Labate AM et al. Flutamide-induced toxic hepatitis. Potential utility of ursodeoxycholic acid administration in toxic hepatitis. Dig Dis Sci 1996; 41 (11): 2219-2221
170. Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002; 50 (3): 436-439
171. Taillan B, Chichmanian RM, Fuzibet JG et al. Jaundice caused by rifampicin: 3 cases. Rev Med Interne 1989; 10 (5): 409-411
172. Poupon RY, Meyniel D, Petit J et al. Cholestatic hepatitis during treatment with I.N.H. and rifampicin: arguments in favour of the hepatotoxicity of rifampicin (author's transl). Ann Med Interne (Paris) 1979; 130 (6-7): 371-375